Artikel
Herpes Zoster in Patients with Moderate to Severe Rheumatoid Arthritis Treated with Baricitinib
Suche in Medline nach
Autoren
-
Kevin Winthrop
- Divisions of Infectious diseases, Oregon Health & Science University, Portland, United States
-
SM Lindsey
- Ochsner Medical Center, Baton Rouge, USA
-
Michael E. Weinblatt
- Brigham and Women’s Hospital, Division of Rheumatology, Immunology and Allergy, Boston, United States of America
-
Tsutomu Takeuchi
- Keio University School of Medicine, Tokyo, Japan
-
David Hyslop
- Eli Lilly and Company, Indianapolis, USA
-
Maher Issa
- Eli Lilly and Company, Indianapolis, USA
-
Lei Chen
- Eli Lilly and Company, Indianapolis, USA
-
Christina Dickson
- Eli Lilly and Company, Indianapolis, USA
-
John Bradley
- Eli Lilly and Company, Indianapolis, USA
-
R Fleischmann
- University of Texas Southwestern Medical Center, Dallas, United States of America
-
Christina Steinmüller
- Lilly Deutschland GmbH, Bad Homburg
| Veröffentlicht: | 4. September 2017 |
|---|
Gliederung
Text
Background: Compared to the general population, rheumatoid arthritis (RA) patients (pts) have increased risk of herpes zoster (HZ), that is associated with various biologic DMARDs and JAK inhibitors. The aim of this analysis was to evaluate HZ in RA pts treated with baricitinib (bari), an oral JAK1/JAK2 inhibitor in development for the treatment of RA.
Methods: Data were pooled from completed Phase (Ph) 1, 2, and 3 studies, and an ongoing long-term extension (LTE) study of bari in RA pts (data cutoff January 1, 2016). HZ events were identified using MedDRA preferred terms related to HZ. The incidence of HZ was evaluated for all RA pts who ever received bari (any dose, including LTE data), pts in the 6 randomised, placebo [PBO]-controlled studies (0-24 weeks, DMARD-inadequate responders), and pts in individual active-controlled studies with methotrexate MTX (DMARD-naive: RA BEGIN) and adalimumab (ADA) (ADA; MTX-inadequate responder: RA BEAM). Incidence rate (IR) was calculated as the number of pts with an HZ event per 100 patient-years of observation (PYO) with exposure censored at event date. The Mantel-Haenszel method was used for between treatment group comparisons.
Results: In the all Bari group (1 Ph 1, 3 Ph 2, 4 Ph 3, and 1 ongoing LTE; 3492 pts, 5141 PYO), treatment-emergent HZ was reported in 170 pts (IR=3.3) (Figure 1[Fig. 1]). In the PBO-controlled studies HZ rates for bari 4 mg were significantly increased compared to PBO (IR difference [95%CI]: 3.2 [1.0, 5.4]) and were comparable to ADA in RA-BEAM. The majority of HZ events (95%) were reported as mild or moderate in severity; few were disseminated or complicated (11 distributed beyond primary or adjacent cutaneous dermatomes, 3 associated with facial nerve palsy, no visceral events). Rates appeared higher in Japan and in patients with advancing age, but not with longer RA duration, or corticosteroid use, and decreased with prolonged exposure.
Conclusion: In these integrated analyses, treatment with bari was associated with an increased risk of HZ compared to PBO, with an overall IR of 3.3/100 PYO in patients with RA. Rates appeared to diminish with prolonged exposure.
